Ads
related to: medications that cause hyperphosphatemia- Phosphate Binder FAQs
Get Answers To Frequently Asked
Phosphate Binder Questions.
- How The Treatment Works
Learn How A Phosphate Binder
Treatment Works - Watch A Video.
- Impact Of High Phosphorus
Learn More About The Impact
Of High Phosphorus Levels.
- Savings Information
Download A Savings Card For A
Phosphate Binder Treatment Option.
- Dialysis Patient Support
Read Helpful Resources & Visit An
Official Phosphate Binder Site.
- Your Guide To Phosphorus
Download The Patient Guide
To Learn More About Phosphorus.
- Phosphate Binder FAQs
Search results
Results From The WOW.Com Content Network
Hyperphosphatemia. Hyperphosphatemia is an electrolyte disorder in which there is an elevated level of phosphate in the blood. [1] Most people have no symptoms while others develop calcium deposits in the soft tissue. [1] The disorder is often accompanied by low calcium blood levels, which can result in muscle spasms.
Sevelamer (rINN) is a phosphate binding medication used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. Sevelamer was invented and developed by GelTex Pharmaceuticals. Sevelamer is marketed by Sanofi under the brand names Renagel (sevelamer ...
Phosphate binder. Phosphate binders are medications used to reduce the absorption of dietary phosphate; they are taken along with meals and snacks. They are frequently used in people with chronic kidney failure (CKF), who are less able to excrete phosphate, resulting in an elevated serum phosphate.
Erythropoiesis-stimulating agents (ESA) are medications which stimulate the bone marrow to make red blood cells. [1] They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in HIV/AIDS. [1][2] In these situations they decrease the need for blood transfusions. [2]
Sucroferric oxyhydroxide. Sucroferric oxyhydroxide, sold under the brand name Velphoro, is a non-calcium, iron-based phosphate binder used for the control of serum phosphorus levels in adults with chronic kidney disease (CKD) on haemodialysis (HD) or peritoneal dialysis (PD). [6] It is used in form of chewable tablets.
Renal osteodystrophy is currently defined as an alteration of bone morphology in patients with chronic kidney disease (CKD). [1] It is one measure of the skeletal component of the systemic disorder of chronic kidney disease-mineral and bone disorder (CKD-MBD). [1][2][3] The term "renal osteodystrophy" was coined in 1943, [4] 60 years after an ...
Hyperphosphatemia causes acute kidney injury in tumor lysis syndrome, because of deposition of calcium phosphate crystals in the kidney parenchyma. [2] Hypocalcemia. Because of the hyperphosphatemia, calcium is precipitated to form calcium phosphate, leading to hypocalcemia. [2] Symptoms of hypocalcemia include (but are not limited to): [9] tetany
2% (people in hospital) [1] Hypophosphatemia is an electrolyte disorder in which there is a low level of phosphate in the blood. [1] Symptoms may include weakness, trouble breathing, and loss of appetite. [1] Complications may include seizures, coma, rhabdomyolysis, or softening of the bones.